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PObesity Is a Major Determinant of
Radiation Dose in Patients Undergoing
Pulmonary Vein Isolation for Atrial Fibrillation
Joris Ector, MD,* Octavian Dragusin, MSC,† Bert Adriaenssens, MD,* Wim Huybrechts, MD,*
Rik Willems, MD, PHD,* Hugo Ector, MD, PHD,* Hein Heidbüchel, MD, PHD*
Leuven, Belgium
Objectives This study sought to evaluate the impact of obesity on patient radiation dose during atrial fibrillation (AF) abla-
tion procedures under fluoroscopic guidance.
Background Obesity is a risk factor for AF and its recurrence after ablation. It increases patient radiation dose during fluoro-
scopic imaging, but this effect has not been quantified for AF ablation procedures.
Methods Effective radiation dose and lifetime attributable cancer risk were calculated from dose-area product (DAP) measure-
ments in 85 patients undergoing AF ablation guided by biplane low-frequency pulsed fluoroscopy (3 frames/s). Three
dose calculation methods were used (Monte Carlo simulation, dose conversion coefficients, and depth-profile dose
curves).
Results Median DAP for all patients was 119.6 Gy·cm2 (range 13.9 to 446.3 Gy·cm2) for procedures with a median dura-
tion of 4 h and 83  26 min of fluoroscopy. Body mass index was a more important determinant of DAP than
total fluoroscopy time (r  0.74 vs. 0.37, p  0.001), with mean DAP values per hour of fluoroscopy of 58  40
Gy·cm2, 110  43 Gy·cm2, and 184  79 Gy·cm2 in normal, overweight, and obese patients, respectively. The
corresponding effective radiation doses for AF ablation procedures were 15.2  7.8 mSv, 26.7  11.6 mSv, and
39.0  15.2 mSv, respectively (Monte Carlo). Use of conversion coefficients resulted in higher effective dose
estimates than other methods, particularly in obese patients. Mean attributable lifetime risk of all-cancer mortal-
ity was 0.060%, 0.100%, and 0.149%, depending on weight class.
Conclusions Obese patients receive more than twice the effective radiation dose of normal-weight patients during AF abla-
tion procedures. Obesity needs to be considered in the risk-benefit ratio of AF ablation and should prompt fur-
ther measures to reduce radiation exposure. (J Am Coll Cardiol 2007;50:234–42) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.040e
E
c
r
c
s
S
g
d
c
w
p
a
e
catheter ablation of atrial fibrillation (AF) is gradually
aining worldwide acceptance as an effective therapy for
atients with symptomatic and drug-refractory AF. In spite
f a growing use of nonfluoroscopic mapping systems to
uide these complex procedures, many centers still rely on
iplane fluoroscopic guidance for catheter navigation and
blation. A worldwide survey on AF ablation conducted
etween 1995 and 2002 showed that 77% of participating
enters used a lasso approach with fluoroscopic guidance to
rom the Departments of *Cardiology and †Radiology, University Hospital Gas-
huisberg, University of Leuven, Leuven, Belgium. Dr. Heidbüchel is a member of the
cientific advisory board of Biosense Webster, Inc. and St. Jude Medical, Inc. Dr. Joris
ctor is a Research Assistant and Dr. Heidbüchel is a Fundamental Clinical
nvestigator of the Fund for Scientific Research, Flanders. Dr. Heidbüchel is holder
f the AstraZeneca Chair in Cardiac Electrophysiology, University of Leuven.i
Manuscript received August 31, 2006; revised manuscript received March 15, 2007,
ccepted March 20, 2007.lectrically isolate pulmonary veins from the left atrium (1).
ven when other systems are used, fluoroscopy forms the
ornerstone of the procedure.
Like all ionizing radiation, fluoroscopy is associated with
isks. Skin damage at the site of the X-ray beam entrance
an occur above a certain radiation dose, with increasing
everity at higher doses (i.e., a deterministic effect) (2).
tochastic effects such as radiation-induced cancer and
enetic defects occur with a higher probability at higher
oses, without a distinct dose threshold. Modern fluoros-
opy systems operate under automatic exposure control,
ith tube voltage (kV) and tube current (mA) adjusted to
atient attenuation. They therefore result in a higher radi-
tion load in obese patients. The influence of patient size on
ffective doses during these procedures is generally not
onsidered and not documented. This may be especially
mportant, however, in candidates for AF ablation because
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July 17, 2007:234–42 Obesity and Radiation Dose in AF Ablationecent data showed an increased prevalence of AF in obese
atients (3) and a higher recurrence rate after ablation (4).
urthermore, the increase in patient radiation dose caused
y obesity is expected to be more pronounced for AF
blation than for other interventional cardiac procedures
ecause the former generally requires longer procedures and
uoroscopy times.
The goal of our study was to calculate effective radiation
oses in a large group of patients undergoing pulmonary
ein isolation (PVI) and to determine the influence of
atient body mass on this dose and its associated stochastic
nd deterministic risks.
ethods
atients and procedures. We report on 85 patients (64
en and 21 women) who underwent a first radiofrequency
blation of focally induced paroxysmal or persistent AF.
atients in whom important underlying atrial structural
hanges were assumed (dilated left atrium, congestive heart
ailure, older age) were not considered for ablation in our
enter. Data on patient height, weight, and body mass index
BMI) were collected as part of the clinical routine. The
MI was classified as normal (25 kg/m2), overweight (25
o 30 kg/m2), and obese (30 kg/m2) according to the
orld Health Organization/National Institutes of Health
lassification scheme (5).
Ablation was performed under general anesthesia with
ropofol and mechanical ventilation. All catheters were
ntroduced via femoral veins. Transseptal catheterization
as performed using 2 transseptal sheaths (SR 0, St. Jude
edical, Daig Division, Inc., Minnetonka, Minnesota).
ntravenous heparin was given to maintain an activated
lotting time of 250 to 350 s during the procedure. Mapping of
ulmonary vein (PV) potentials was performed with a de-
ectable decapolar catheter with a distal ring configuration
Lasso, Cordis-Webster, Diamond Bar, California). Abla-
ion was performed using temperature feedback with a
arget temperature of 50oC and a maximum power output of
0 W. The end point for PV isolation was the creation of
idirectional conduction block from atrium to PV and vice
ersa. All 4 PVs were isolated in 73 of 85 (86%) patients,
hereas only arrhythmogenic PVs were targeted in the
emaining 12 patients (6). The PV angiograms were per-
ormed before and after PV isolation. Linear ablation
esions from the left inferior PV toward the mitral valve
nd/or in the roof of the left atrium were applied in 14
atients (16%) if AF was still inducible after PVI. The
nferior flutter isthmus between tricuspid ring and inferior
aval vein orifice was ablated in 62 of 85 patients (73%)
uring the same procedure (and was ablated before in 19
thers). Flutter ablation was guided by right atrial angio-
raphy in 52 of 62 patients (84%) (7). tiplane fluoroscopy and dose-
rea product (DAP) measure-
ents. All procedures were per-
ormed under fluoroscopic guid-
nce with a Coroskop C biplane
mage intensifier system (Siemens,
rlangen, Germany). The system
as routinely set to pulsed fluo-
oscopy at 3 frames/s and a cine
rame rate of 12.5 frames/s to
inimize radiation exposure.
he image intensifier diameter
f 23 cm was used for all patients
ith beam collimation to the re-
ion of interest. Standard 30o
ight anterior oblique (RAO)/
0o left anterior oblique (LAO)
uoroscopic view angles were ad-
usted to the intracardiac catheter positions as outlined
reviously (8). The half-value layer (HVL) of each tube was
.4, respectively, 5.6 mm of aluminum at 80 kV.
Radiation dose was quantified with DAP meters incor-
orated in the fluoroscopy unit. These DAP meters use an
ir ionization chamber mounted just beyond the X-ray
ollimators and integrate exposure over the entire image
eld. The DAP meters were calibrated yearly. The DAP
as recorded (in Gy·cm2) as a total for both X-ray tubes,
ogether with the procedure time and total fluoroscopy time
n minutes. The DAP measurements have been proven to
orrelate reasonably well with effective radiation dose, and
herefore reflect the probability of stochastic effects (9,10).
onversion of DAP measurements to effective dose. The
oncept of effective dose is used in radiation protection to
ompare the stochastic risk of a nonuniform exposure of
onizing radiation with the risks caused by a uniform exposure
o the whole body (11). The effective dose is expressed in
ievert (Sv) or millisievert (mSv), and is found by calculating a
eighted average of the equivalent dose to different body
issues, with the weighting factors designed to reflect the
ifferent radiosensitivities of the tissues. This parameter per-
its comparison of risks among different individuals and
mong different imaging modalities (e.g., comparison of effec-
ive dose between coronary angiogram and computed tomog-
aphy coronary angiography (12).
In this study, the effective dose was calculated for each
atient using 3 methods. The primary method used a
C-based X-ray Monte Carlo program, PCXMC (Radia-
ion and Nuclear Safety Agency, Helsinki, Finland) (13).
his software allows Monte Carlo simulation of fluoro-
copic radiation exposure to a hermaphrodite phantom
modified Cristy-phantom (14)] based on fluoroscopic view
ngles, patient weight and height, field size, and focus to
kin distance. Because DAP values were only recorded by
he fluoroscopy system as a total for both RAO and LAO
maging planes, the relative contribution of each plane to
Abbreviations
and Acronyms
AF  atrial fibrillation
BMI  body mass index
DAP  dose-area product
HVL  half-value layer
LAO  left anterior oblique
NRPB  National
Radiological Protection
Board
PSD  peak skin dose
PV  pulmonary vein
PVI  pulmonary vein
isolation
RAO  right anterior
obliqueotal DAP values was estimated in 5 reference procedures
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Obesity and Radiation Dose in AF Ablation July 17, 2007:234–42nd was found to be about equal for both. Therefore, DAP
alues were divided by 2 to calculate effective dose contri-
ution from each imaging plane. We used 13 13-cm field
imensions at the entrance of the patient’s skin, a 60-cm
ocus-skin distance, an HVL of 5.5 mm aluminum, and an
0-kV beam to further characterize the fluoroscopic expo-
ure in all patients, based on the characteristics determined
rom the reference procedures. Effective dose results from
his method were used for calculation of the radiation-
nduced lifetime attributable risk for cancer.
The second method used to calculate effective dose from
AP measurements was based on dose conversion coeffi-
ients (15). This method is simpler because it only requires
ultiplying the DAP measurements with a coefficient to
stimate effective dose. However, conversion coefficients are
nly available for a limited number of fluoroscopic projec-
ions, are not adapted to different patient sizes, and depend
n the fluoroscopic protocol used in different centers.
onversion coefficients developed by the National Radio-
ogical Protection Board (NRPB) (16) have been most
requently used in previous studies (17,18). We used the
RPB dose conversion coefficients (80 kV, 5.0 mm Al
VL) for the 45o RAO and 45o LAO projections of the
eart and compared these estimates with the results of our
oftware-based simulation.
In the third method, effective dose was calculated with
oftware based on depth dose and profile curves (WinODS,
TI Electronics AB, Mölndal, Sweden). This software uses
n Alderson-Rando type phantom model, adjusted to each
atient’s height, weight, and gender. The weight of the
atient is compared with the mean weight of the population
aving the same height as the patient. If the patient is
eavier than the statistical mean, adipose tissue is being
dded between the contour and the organs of the phantom.
he addition of adipose tissue is a feature not used in
CXMC, which only applies a scaling factor to adjust for
he patient’s height and weight. Calculation in WinODS
as performed with the same exposure parameters (field
imensions, focus-skin distance, HVL, and tube voltage) as
or the PCXMC software.
stimation of lifetime attributable cancer risk from
VI. Effective dose values from the PCXMC software were
sed to calculate the radiation-induced lifetime attributable risk
or cancer incidence and cancer mortality in each patient, based
n the risk estimates recently published in the BEIR VII report
n the health risks from exposure to low levels of ionizing
adiation (19). The cancer risk estimates in the BEIR VII
eport are based on the linear-no-threshold risk model, assum-
ng that the risk of cancer proceeds in a linear fashion at lower
oses without a threshold and that the smallest dose has the
otential to cause a small increase in risk to humans. To
alculate the lifetime attributable risk for cancer incidence and
ortality at patient-specific ages, linear interpolation was usedor ages not explicitly provided in the BEIR VII report. atatistical Analysis
ummary values are given as mean  SD or median for
ot-normally-distributed values. The Shapiro-Wilk W test
as used to test for normality. Comparisons between
ontinuous variables in the 3 patient groups were made by
ne-way analysis of variance with Scheffe post-hoc analysis.
ifferences in proportions between groups were evaluated
ith the Fisher exact test. A value of p  0.05 was
onsidered significant.
A Pearson correlation coefficient was calculated for sim-
le linear regression analysis, and a Hotteling t test was used
o assess differences between related correlations. Multiple
inear regression was performed to adjust for patient gender,
MI, fluoroscopy time, and addition of a flutter ablation or
inear lesions.
The authors had full access to the data and take respon-
ibility for its integrity. All authors have read and agree to
he manuscript as written.
esults
atients and procedures. Patient and procedural charac-
eristics are summarized in Table 1. Mean patient BMI was
6.6 4.1 kg/m2, corresponding well with values previously
ublished in larger groups of AF patients (20). Sixteen
atients (19%) had a BMI 30 kg/m2, the criterion for
besity.
Nineteen patients had already undergone ablation for
trial flutter in the past. Pulmonary vein isolation and
avotricuspid isthmus ablation were acutely successful in all
atients in whom they were performed. This required a
ean fluoroscopy time of 83  26 min in procedures with
median duration of 4 h. Procedural and fluoroscopy times
ended to be somewhat higher in overweight and obese
atients, although these differences were not statistically
ignificant (procedural time 237  46 min, 258  76 min,
nd 266  54 min in normal, overweight, and obese
atient and Procedure Characteristics
Table 1 Patient and Procedure Characteristics
Parameters
Age, yrs 49 9 (64 male, 21 female)
Weight, kg 82 15
Height, cm 175 9
BMI, kg/m2 26.6 4.1
BMI 25 kg/m2, n (%) 28 (33)
BMI 25 to 30 kg/m2, n (%) 41 (48)
BMI 30 kg/m2, n (%) 16 (19)
Procedure time, min 240 (140–510)
Fluoroscopy time, min 83 26
RAO angulation, o 44 9
LAO angulation, o 47 9
DAP value, Gy·cm2 119.6 (13.9–446.3)
Effective dose,* mSv 22.4 (3.1–71.4)
ata are mean  SD or median (range) for not-normally-distributed variables. *Effective dose as
alculated with PCXMC simulation software.
BMI body mass index; DAP dose-area product; LAO left anterior oblique view; RAO right
nterior oblique view.
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July 17, 2007:234–42 Obesity and Radiation Dose in AF Ablationatients, respectively, p  0.25; fluoroscopy time 76  28
in, 85  25 min, and 89  24 min, respectively, p 
.22). Nine patients (11%) required a repeat PVI procedure
or recurrent AF. These repeat procedures were not in-
luded in this study.
AP and influence of patient size and body mass. De-
pite the use of pulsed fluoroscopy at 3 frames/s, PVI
rocedures resulted in a relatively high patient radiation
xposure with a median DAP value of 119.6 Gy·cm2 (range
3.9 to 446.3 Gy·cm2). The correlation between fluoroscopy
ime and DAP was relatively weak (r  0.37, p  0.001)
Fig. 1A). Figure 1B shows that there is a significantly
tronger influence of BMI on patient radiation dose (r 
.74, p  0.001). The strong correlation between BMI and
AP remained highly significant when multivariably cor-
ected for patient gender, fluoroscopy time, and addition of
flutter ablation or linear lesions, with partial correlation
oefficients of 0.74 for BMI (p  0.001) and 0.22 for
uoroscopy time (p  0.04). The addition of a right atrial
utter ablation was also significantly correlated with total
AP (partial correlation coefficient 0.23, p  0.001). The
ercentage of patients undergoing left atrial linear ablation
as comparable in the groups of normal-weight and obese
atients (28.6% vs. 25.0%), and the addition of linear lesions
id not significantly correlate with total DAP on multivar-
ate analysis. The mean radiation doses for patients in the 3
MI groups are represented in Figure 2, expressed both as
AP for the total procedure and per hour of fluoroscopy.
uring 1 h of fluoroscopy, obese patients received 3.2 times
he DAP of patients with a normal BMI, resulting in mean
AP values of 184  79 and 58  40 Gy·cm2/h respec-
ively (p  0.001).
Figure 1 Patient Radiation Dose Versus Fluoroscopy Time and
Scatter plots showing the relationship between patient radiation dose and total flu
relation between BMI and radiation dose than between fluoroscopy time and radia
lation coefficients; R  correlation coefficients.1,2A DAP trigger level of 300 Gy·cm2 has been proposed for
nterventional cardiac procedures to alert the operator for
ossible skin injury of the patient (9,17). A DAP value
300 Gy·cm2 occurred in 6 procedures (7%), and 5 of these
rocedures involved obese patients (p  0.001). No clinical
anifestations of radiodermatitis were evident after the
rocedure and at 6-week follow-up, and there were no
eports of any adverse effects from patients.
ffective dose. The median effective dose for all proce-
ures, as calculated with the PCXMC software (method 1),
as 22.4 mSv with a range from 3.1 to 71.4 mSv. Again, the
ffective dose was highly dependent on patient size (Fig. 3).
or obese patients, the mean total effective dose for a PVI
rocedure was 39.0  15.2 mSv, compared with 15.2  7.8
Sv for patients with a normal BMI (p  0.001). When
alculated per hour of fluoroscopy, obese patients received a
.2-fold higher effective dose (27.3 vs. 12.5 mSv/h).
Calculation with the NRPB conversion coefficients
method 2; RAO 0.251 mSv·Gy1cm2, LAO: 0.223
Sv·Gy1cm2) resulted in higher estimates of the received
ffective dose compared to the PCXMC calculations. The
ifference between the 2 calculation methods increased with
igher BMI values and was significant in the overweight
nd obese patient groups (Figs. 3 and 4A). Therefore,
ffective dose estimations of the PCXMC program were
sed to calculate a local center-specific dose conversion
oefficient from total DAP to effective dose during PVI
rocedures in our center. The calculated conversion coeffi-
ient was 0.188 mSv·Gy1cm2 for the entire patient
roup, but was also highly dependent on patient size: 0.218
Sv·Gy1cm2 for patients with normal BMI versus 0.180
py time (A) and body mass index (BMI) (B). There is a significantly stronger cor-
se. DAP  dose-area product; PDiff(R1-R2)  p value for difference between corre-BMI
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Obesity and Radiation Dose in AF Ablation July 17, 2007:234–42nd 0.154 mSv·Gy1cm2 for overweight and obese pa-
ients respectively (p  0.001 for both).
Calculation with the WinODS software (method 3)
esulted in slightly (but not significantly) higher effective
ose estimates than with the PCXMC software (Fig. 3).
igher effective dose estimates in female patients were the
Figure 2 DAP Values According to BMI
Dose area product values (in Gy·cm2) according to BMI, expressed both for
total PVI procedure and per hour of fluoroscopy. Bars and numbers represent
mean DAP values, whiskers represent 95% confidence intervals. PVI  pulmo-
nary vein isolation; other abbreviations as in Figure 1.
Figure 3 Effective Dose Values According to BMI
Effective dose (in mSv) according to BMI for total PVI procedure (A) and per hour
cients, and WinODS software. Bars and numbers represent mean effective dose, w
mated with National Radiological Protection Board (NRPB) conversion coefficients
kg/m2. PVI  pulmonary vein isolation.ain reason for this discrepancy (Fig. 4B). This difference
as, however, not statistically significant even for the group
f female patients only, given the small number of women
ncluded in the study (n 21, p 0.13). When considering
nly male patients, the differences in the mean effective dose
n the 3 BMI categories were 1 mSv for both programs
PCXMC vs. WinODS: 16.5 vs. 15.5 mSv for normal
eight, 26.6 vs. 26.5 mSv for overweight, and 44.0 vs. 44.5
Sv for obese patients). The higher estimates for female
atients compared with Monte Carlo-based dose determi-
ations have been reported before for WinODS and are
ainly caused by anatomical differences between the phan-
om models (21).
adiation-induced lifetime attributable cancer risk. The
ifetime risks for the incidence and mortality of cancer
ttributable to an effective radiation dose associated with
VI in our center are represented in Table 2. To put
hese risks into perspective, the baseline lifetime risk for
olid cancer mortality in the general population is also
ncluded (19).
iscussion
ur study is the first to report DAP measurements of the
adiation exposure in a large group of patients undergoing
VI for AF to calculate effective dose and related risks. It
hows that these procedures are associated with a relatively
igh patient radiation exposure despite the use of pulsed
uoroscopy at 3 frames/s. Moreover, our findings highlight
he important effect of patient mass on effective dose during
hese procedures: the fact that patient BMI is a more
roscopy (B), as calculated with the PCXMC software, dose conversion coeffi-
rs represent 95% confidence intervals. *Significantly higher effective doses esti-
PCXMC calculations occur in patient groups with body mass index (BMI) 25of fluo
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July 17, 2007:234–42 Obesity and Radiation Dose in AF Ablationmportant determinant of the effective dose than total
uoroscopy time is generally not recognized. This finding is
xplained by the automatic exposure control used in current
uoroscopy systems, adapting tube voltage (kV) and tube
urrent (mA) to preserve radiation levels at the image
eceptor for different levels of patient attenuation. It impli-
ates that the indication for ablation should be weighed
ore carefully in obese patients, and that these patients in
articular would benefit from the lower radiation exposure
ssociated with nonfluoroscopic mapping systems.
atient radiation exposure during AF ablation. Few data
ave been published regarding patient radiation exposure
uring AF ablation. Measurement of peak skin doses
PSDs) were performed in 2 previous reports to estimate
atient radiation exposure. Macle et al. (22) reported on the
Figure 4 Relationship Between Effective Dose Values
Calculated With 3 Different Methods
Scatter plots illustrating the relationship between effective doses calculated
with (A) PCXMC and NRPB conversion coefficients and (B) PCXMC and
WinODS software for each patient. (A) Although both methods give similar
results in normal-weight patients, PCXMC generates lower effective dose esti-
mates than conversion coefficient estimates in overweight and especially
obese patients. (B) Excellent agreement between effective dose calculations
with PCXMC and WinODS for male patients, regardless of BMI. For female
patients, WinODS calculations result in higher effective dose estimates. Abbre-
viations as in Figure 3.adiation dose measured with dosimeters placed over the cyphoid in 43 patients undergoing ablation for paroxysmal
F. They measured a median PSD of 1.110 mSv. However,
he use of only one dosimeter, possibly not at the focal point
f radiation, probably led to a great underestimation of
SD. This problem was overcome in a study by Lickfett
t al. (23), by using a vest containing 50 to 60 dosimeters to
easure PSD in 15 patients undergoing AF ablation. They
easured a PSD of 1.0 0.5 Gy in the RAO and 1.5 0.4
y in the LAO projection, doses approximately 1,000-fold
igher than those reported by Macle et al. (22). They
stimated an overall mean effective dose of 24.4 mSv in
atients undergoing AF ablation.
Estimation of effective doses based on DAP measure-
ents have only been published in 2 patients undergoing
F ablation, included in a study by Efstathopoulos et al.
24). They reported a DAP of 133.4 Gy·cm2 and effective
oses of 16.6 to 30.1 mSv, according to calculations based
n dose conversion coefficients and computer simulation
espectively.
Our results illustrate that the use of NRPB conversion
oefficients (16), published for patients with standard di-
ensions (weight 73 kg, height 179 cm, BMI 22.8 kg/m2),
esult in higher effective dose estimates when they are
pplied to DAP measurements from obese patients. This
nding is explained by the fact that obese patients provide
ore natural shielding of the sensitive organs to the
adiation beam by the presence of a larger amount of fat
issue. From the geometrical point of view, it is possible that
or certain tube angulations, the traveling distance of pho-
ons from the entrance skin point to affected organs is
ncreased, consequently reducing the organ dose and effec-
ive dose. A certain DAP value therefore results in a lower
ffective dose in obese than in normal-weight patients. This
an be derived from our study by: 1) the lower local
onversion coefficients calculated (based on Monte Carlo
imulation) for obese patients; and 2) the fact that increases
n effective dose between different BMI categories were
maller than the corresponding increases in DAP values.
onsequently, published conversion coefficients have to be
sed cautiously, not only considering the used fluoroscopy
rotocol but also the size of the patient (25). Preferably,
very laboratory should determine its own conversion coef-
cients for the 3 BMI groups.
besity and patient radiation exposure: clinical implica-
ions. The relationship between patient weight and radia-
ion dose has been established in invasive cardiologic studies
ther than AF ablation. Kuon et al. (26) found a relation of
atient dose rate (DAP/time) and BMI comparable to the
ne found in our study. The resulting increase in dose per
rocedure, however, is much higher in our series because of
he complex nature of AF ablation and associated long
uoroscopy times. The correlation between BMI and DAP
n our study is much stronger than reported for other
nvasive cardiac studies (r  0.74 vs. 0.37 as reported by
uon et al. [26]) because the relative differences in fluoros-opy time are more important during short procedures.
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Obesity and Radiation Dose in AF Ablation July 17, 2007:234–42uring long procedures, time differences are relatively
maller and variation in dose rates related to BMI have a
arger impact on the cumulative dose.
The high radiation exposure (39.0  15.2 mSv) observed
n obese patients in our study results in a worse risk-benefit
atio and should be considered when weighing the indica-
ion for AF ablation under fluoroscopic guidance. Several
onsiderations underscore the clinical importance of this
nding. Obesity is a rapidly growing problem in an increas-
ng number of countries worldwide, with a prevalence of
30% in the U.S. (27). It has been shown to be an
ndependent risk factor for AF with an adjusted 50% risk
ncrease for developing AF (3). Furthermore, recent data
uggest that obese patients have higher rates of AF recur-
ence after radiofrequency ablation and are therefore more
ikely to undergo repeat procedures (4).
imiting radiation exposure in patients referred for AF
blation. The most important way to reduce radiation
xposure during AF ablation is the use of nonfluoroscopic
apping systems when available, allowing a reduction of
uoroscopy time in the range of 25% to 50% (28–30). If
uoroscopic guidance is used, minimizing fluoroscopy time
s much as possible and use of pulsed fluoroscopy are
andatory. Aufrichtig et al. (31) showed average dose
avings of 22%, 49%, and almost 80% at 15, 7.5, and 3
rames/s, respectively (32). The use of flat-panel detectors
nstead of image intensifiers in newer fluoroscopy systems
ossibly allows a dose reduction because of their higher
etector sensitivity (i.e., detective quantum efficiency) (33).
owever, the use of flat-panel detectors does not automat-
cally translate into better image quality and dose efficiency
n clinical practice, because many other parameters influence
he patient radiation dose in a clinical setting (34,35). New
eatures such as retrospective fluoroscopy storage and dif-
erent operational dose levels for fluoroscopy nevertheless
ffer additional opportunities for patient dose reduction.
An additional recent source of patient radiation exposure
isk Estimates for Cancer Incidence and Cancer Mortalityttributable to Radiation Exposure During Atrial Fibrill tion Ablatio
Table 2 Risk Estimates for Cancer Incidence and Cancer MortaAttributable to Radiation Exposure During Atrial Fibrilla
Effective Dose (mSn (M/F) Age, yrs
BMI 25 kg/m2 28 (17/11) 48 10 15.2 7.9
BMI 25–30 kg/m2 41 (36/5) 51 7 26.8 11.6
BMI 30 kg/m2 16 (11/5) 46 10 39.0 14.7
All patients 85 (64/21) 49 9 25.0 13.8
ifetime risks for cancer incidence and cancer mortality attributable to the effective doses ass
ender-specific risk estimates are represented for each body mass index (BMI) category and for t
atients. As a reference, the baseline risk of mortality caused by solid cancers (excluding thyroid a
omen, respectively.s the imaging of the left atrium and PVs by multislice cardiac computed tomography, which is increasingly per-
ormed before AF ablation. It can add an additional effective
ose in the range of 5 to 20 mSv, which is proportionally
mportant compared with the dose of the ablation procedure
tself (median 22.4 mSv) (Table 1) (36). Again, patient
eight is likely to be a strong determinant of the computed
omography-related dose. When available, gadolinium-
nhanced magnetic resonance imaging angiography is
herefore preferable given the lack of extra radiation expo-
ure to the patient.
adiation-induced carcinogenic and genetic effects. Data
n the health effects of ionizing radiation are largely based
n studies on survivors of the Hiroshima and Nagasaki
tomic bombs. Although the atomic bomb survivor analyses
ften have been considered as high-dose studies, in fact,
50% of the exposed individuals in the cohort (26,300
ndividuals) received doses 50 mSv (37). Based on these
pidemiologic data, good evidence exists of an increased
ancer risk in humans for an acute exposure at doses above
0 to 50 mSv (37). At lower doses, epidemiologic data alone
re insufficient to establish the shape of the dose–response
elationship, and risk modeling must be performed. Accord-
ng to the linear-no-threshold risk model adopted in the
ecent BEIR VII report (19), the risk for solid cancers at low
oses (100 mSv) can be estimated by linear extrapolation.
his assumption is, however, not uniformly accepted and is
till controversial. For example, a comparable report from
he French National Academy of Medicine, although
argely based on the same data, doubts the validity of the
inear-no-threshold risk model in the evaluation of the
arcinogenic risk of low doses (100 mSv) and even more
or very low doses (10 mSv) (38). This lack of consensus
eflects the complexity of the radiation dose-response phe-
omenon, and further research is needed to reduce uncer-
ainty and further elucidate various mechanisms by which
ow-level radiation may induce cell damage.
The lifetime attributable risks for cancer incidence and
Ablation
Lifetime Attributable Risk (%)
Baseline Lifetime
Risk (%)
All Cancer Incidence All Cancer Mortality
Solid Cancer
Mortality
0.100 0.060 0.060 0.033 — —
(1/1,000) (1/1,666)
0.158 0.080 0.100 0.048 — —
(1/633) (1/1,000)
0.247 0.083 0.149 0.049 — —
(1/405) (1/671)
0.156 0.090 0.095 0.053 22.1 17.5
(1/641) (1/1,053) (1/5) (1/6)
with pulmonary vein isolation in our center. Data are given as mean  SD. Age-specific and
re patient population. Mean lifetime attributable risk percentages are also represented as “1/n”
melanoma skin cancers) for the general U.S. population is given in the right column for men andn
lity
tion
v)
ociated
he entiancer mortality should not be misinterpreted and must
b
c
h
e
i
a
m
S
m
b
P
n
f
c
g
r
t
p
d
R
0
L
v
f
a
v
p
D
m
d
C
D
a
h
o
t
w
a
c
h
b
R
o
L
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
241JACC Vol. 50, No. 3, 2007 Ector et al.
July 17, 2007:234–42 Obesity and Radiation Dose in AF Ablatione seen in the larger clinical context of lifetime risk of
ancer mortality (Table 2). The risk of genetic effects and
eritable diseases has been found to be very low at doses
ncountered in our patient series. No statistically signif-
cant adverse effects have been detected in children of
tomic bomb survivors subjected to radiation doses of 400
Sv or less (19).
tudy limitations. We did not perform direct measure-
ents of PSD with dosimeters placed at the patient’s
ody surface. The DAP values do not directly reflect
SD, and quantitative evaluation of PSD was therefore
ot a part of this study. The DAP was measured as a total
or fluoroscopy in RAO and LAO projections, including
ine sequences, as this was a limitation of the radio-
raphic equipment. To calculate effective doses, the
elative contribution of RAO and LAO imaging planes
o the total DAP was estimated from a subset of reference
rocedures and not recorded in each individual proce-
ure. The difference in effective dose values calculated for
AO and LAO projections was, however, only 0.002 
.008 mSv/Gy·cm2. Minor changes in the relative RAO/
AO contribution are therefore expected to have only a
ery limited impact on the calculated total effective dose
or these procedures. A 80-kV tube voltage was used in
ll patients to calculate effective doses. Higher tube
oltages (90 to 100 kV) during procedures in obese
atients can lead to higher effective doses for a given
AP value. Our results may therefore even underesti-
ate to some extent the effect of obesity on the effective
ose during these procedures.
onclusions
espite the use of pulsed fluoroscopy at 3 frames/s,
blation of AF under fluoroscopic guidance results in
igh patient radiation exposure. When performed in
bese patients, these procedures are associated with more
han twice the patient effective radiation dose. Together
ith the higher incidence of AF, higher recurrence rate
fter ablation, and presumably higher doses during asso-
iated preprocedural imaging, one needs to consider the
igher carcinogenic risk in these patients in the risk-
enefit evaluation of ablation.
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